← All Articles
Recovery
TB-500 (Thymosin Beta-4): What the Research Shows
Irvine Health Editorial
2025-11-15
11 min read
Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
TB-500 is a synthetic version of a naturally occurring 43-amino-acid peptide fragment of Thymosin Beta-4 (Tβ4) — specifically the actin-binding domain sequence LKKTETQ. Thymosin Beta-4 itself is one of the most abundant and ubiquitous proteins in mammalian cells, originally isolated from the thymus and later found throughout the body. It plays fundamental roles in actin cytoskeleton regulation, cell migration, differentiation, and tissue protection. Research interest in both full-length Tβ4 and the TB-500 fragment has grown considerably over the past two decades, supported in part by NIAID and NIH-funded investigations into wound healing and cardiac repair.
Key Research Areas
Cardiac Repair — Bock-Marquette et al., Nature (2004)
In a landmark study, researchers found that Thymosin Beta-4 could activate cardiac progenitor cells, promoting cardiomyocyte survival and angiogenesis in a mouse model of myocardial infarction. This generated significant NIH-funded research interest in Tβ4 as a potential cardiac repair peptide.
Wound Healing — Philp et al., J Invest Dermatol (2004)
Topical and systemic Thymosin Beta-4 accelerated full-thickness dermal wound healing in rat models by promoting keratinocyte and endothelial cell migration. The authors noted that Tβ4 treatment increased laminin-5 expression and enhanced re-epithelialization.
Anti-inflammatory Effects — Sosne et al., Cornea (2007 and subsequent)
A substantial body of research by Sosne and colleagues documented Tβ4's anti-inflammatory effects in corneal injury models, including NF-κB pathway downregulation. This work has supported clinical trials of Tβ4 eye drops for dry eye and corneal disease.
Neurological Models — Xiong et al., J Neurosci Res (2011)
In rodent models of traumatic brain injury, Thymosin Beta-4 treatment was associated with reduced neuronal death, improved neurological scores, and enhanced angiogenesis in the injury zone compared to controls.
The Actin Sequestration Mechanism
Tβ4's primary intracellular function is to bind G-actin (monomeric actin), maintaining a pool of actin available for rapid polymerization during cell migration and wound healing. By modulating actin dynamics, Tβ4 facilitates the migration of multiple cell types — keratinocytes, endothelial cells, and myofibroblasts — that are critical to tissue repair processes. The LKKTETQ sequence in TB-500 contains the core actin-binding region responsible for this activity.
Important Context
Like BPC-157, TB-500 has not completed large-scale human clinical trials. Full-length Thymosin Beta-4 has advanced further in clinical development: RegeneRx Biopharmaceuticals conducted Phase II trials of Tβ4 eye drops for dry eye and corneal neurotrophic disease. However, injectable TB-500 as used in compounded peptide therapy remains an off-label, investigational application. Safety and pharmacokinetic data in humans are limited, making physician evaluation and monitoring essential for any patient considering this approach.
References
- Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72.
- Philp D, et al. Thymosin beta4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2006;14(4):395-404.
- Sosne G, et al. Thymosin beta-4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci. 2005;46(7):2388-95.
- Xiong Y, et al. Thymosin beta4 improves functional neurological outcome in a rat model of traumatic brain injury. J Neurosci Res. 2011;89(4):601-9.
- Ho EN, et al. Detection of TB-500 and its metabolites in equine plasma and urine by LC-MS/MS. Drug Test Anal. 2012;4(6):454-63.
Explore More Articles
Browse our full library of evidence-based peptide research.
View All Posts
*The assessment made available on the Irvine Health website does not create a doctor-patient relationship between the individual completing the assessment and Irvine Health. Irvine Health partners with a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety. The answers an individual provides to the Irvine Health assessment consequently determine if the individual is screened out of eligibility for medication, and an Irvine Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. Irvine Health clinicians retain the decision to prescribe compounded medications to patients.
All claims and benefits on this website refer to self-reported data from customers on a treatment plan that includes compounded medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3–4 weeks thereafter. Results from compounded medications found on the Irvine Health platform may vary and be affected by an individual’s adherence to the program and their clinician’s recommendations. Compounded peptides and GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider’s medical judgment, which is informed by a telehealth consultation and medical history.
We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Irvine Health does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.
Pharmacy Providers
We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.
*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs, and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.
Medication is included in the cost of the Irvine Health Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by Irvine Health affiliated physicians and licensed professional corporations. No data, photos, claims, or any other information is associated with results derived from clinical trials, studies, or public information and is always representative of Irvine Health patient experience.
Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content.
© 2026 Irvine Health LLC. All rights reserved. 19200 Von Karman Avenue, 4th, 5th, and 6th Floors, Irvine, CA 92612.